This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsIndiva（T8RP）株式概要インディバ社はカナダで大麻と大麻関連製品の生産、加工、販売に従事している。 詳細T8RP ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6報酬過去5年間の収益は年間6.8%増加しました。 リスク分析マイナスの株主資本 キャッシュランウェイが1年未満である 意味のある時価総額がありません ( €4M )株式の流動性は非常に低い +1 さらなるリスクすべてのリスクチェックを見るT8RP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW492,520 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG492,520 investors already sharing narrativesYour Fair Value€Current Price€0.0199.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-16m218m2016201920222025202620282031Revenue CA$217.6mEarnings CA$31.8mAdvancedSet Fair ValueView all narrativesIndiva Limited 競合他社BiofronteraSymbol: XTRA:B8FKMarket cap: €13.7mTFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mCantourage GroupSymbol: XTRA:HIGHMarket cap: €67.6mApontis PharmaSymbol: XTRA:APPHMarket cap: €91.6m価格と性能株価の高値、安値、推移の概要Indiva過去の株価現在の株価CA$0.0152週高値CA$0.04352週安値CA$0.01ベータ1.081ヶ月の変化0%3ヶ月変化-16.67%1年変化-47.37%3年間の変化-96.55%5年間の変化-94.95%IPOからの変化-98.68%最新ニュースお知らせ • Nov 06SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H).SNDL Inc. (NasdaqCM:SNDL) enters into a stalking horse purchase agreement to acquire a remaining majority stake in Indiva Limited (TSXV:NDVA.H) for CAD 22.7 million on July 5, 2024. PricewaterhouseCoopers Inc. (The Monitor) currently estimates the value of the credit bid and cash consideration payable by SNDL under the Bid Agreement to be in the range of approximately CAD 25 million to CAD 28 million. As of July 8, 2024, the Court has approved the sale process. The Transaction is anticipated to close during SNDL's fourth quarter following the receipt of all such approvals. Indiva will seek approval for the Transaction from the Court on or about September 19, 2024. As per filing on August 29, 2024, stalking horse bid of SNDL has been chosen as the successful bid in the acquisition of Indiva. McCarthy Tétrault LLP is acting as legal counsel for SNDL, Bennett Jones LLP is acting as legal counsel for the Indiva Group, and Osler Hoskin & Harcourt LLP is acting as legal counsel for PricewaterhouseCoopers Inc. (the monitor). SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H) on November 4, 2024.お知らせ • Jun 15Indiva Limited Announces Resignation of Rachel Goldman from the BoardIndiva announced that Rachel Goldman resigned from the board of Indiva on June 12, 2024, prior to the board resolving to commence proceedings under the CCAA.New Risk • Jun 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.6m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-CA$1.3m). Market cap is less than US$10m (€4.59m market cap, or US$5.00m). Minor Risk Shareholders have been diluted in the past year (31% increase in shares outstanding).お知らせ • May 24Indiva Limited Provides Earnings Guidance for the Second Quarter of 2024Indiva Limited Provided Earnings Guidance for the second Quarter of 2024. For the quarter, the company expects net revenue will be higher on a sequential basis and year-over-year, expected to exceed $10 million, based on the strength of purchase orders from provincial wholesalers and deliveries to date in the quarter.お知らせ • May 16Indiva Limited to Report Q1, 2024 Results on May 23, 2024Indiva Limited announced that they will report Q1, 2024 results Pre-Market on May 23, 2024お知らせ • Apr 27Indiva Limited Provides Earnings Guidance for the First Quarter and Fiscal Year 2024Indiva Limited Provided Earnings Guidance for the First Quarter and fiscal year 2024. For the quarter, the company expects net revenue will be lower on a sequential basis, primarily due to seasonality, and flat year-over-year, due to the continued growth in Pearls by Grön, and the contribution to revenue from No Future gummies and Indiva Blips offset by Wana converting to contract manufacturing and the loss of lozenge revenue.For the year, the company expects to generate record net revenue, driven by continued strength in its core brands, bolstered by new product introductions and continued efficiency gains at the production facility from automation and process improvements.最新情報をもっと見るRecent updatesお知らせ • Nov 06SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H).SNDL Inc. (NasdaqCM:SNDL) enters into a stalking horse purchase agreement to acquire a remaining majority stake in Indiva Limited (TSXV:NDVA.H) for CAD 22.7 million on July 5, 2024. PricewaterhouseCoopers Inc. (The Monitor) currently estimates the value of the credit bid and cash consideration payable by SNDL under the Bid Agreement to be in the range of approximately CAD 25 million to CAD 28 million. As of July 8, 2024, the Court has approved the sale process. The Transaction is anticipated to close during SNDL's fourth quarter following the receipt of all such approvals. Indiva will seek approval for the Transaction from the Court on or about September 19, 2024. As per filing on August 29, 2024, stalking horse bid of SNDL has been chosen as the successful bid in the acquisition of Indiva. McCarthy Tétrault LLP is acting as legal counsel for SNDL, Bennett Jones LLP is acting as legal counsel for the Indiva Group, and Osler Hoskin & Harcourt LLP is acting as legal counsel for PricewaterhouseCoopers Inc. (the monitor). SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H) on November 4, 2024.お知らせ • Jun 15Indiva Limited Announces Resignation of Rachel Goldman from the BoardIndiva announced that Rachel Goldman resigned from the board of Indiva on June 12, 2024, prior to the board resolving to commence proceedings under the CCAA.New Risk • Jun 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.6m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-CA$1.3m). Market cap is less than US$10m (€4.59m market cap, or US$5.00m). Minor Risk Shareholders have been diluted in the past year (31% increase in shares outstanding).お知らせ • May 24Indiva Limited Provides Earnings Guidance for the Second Quarter of 2024Indiva Limited Provided Earnings Guidance for the second Quarter of 2024. For the quarter, the company expects net revenue will be higher on a sequential basis and year-over-year, expected to exceed $10 million, based on the strength of purchase orders from provincial wholesalers and deliveries to date in the quarter.お知らせ • May 16Indiva Limited to Report Q1, 2024 Results on May 23, 2024Indiva Limited announced that they will report Q1, 2024 results Pre-Market on May 23, 2024お知らせ • Apr 27Indiva Limited Provides Earnings Guidance for the First Quarter and Fiscal Year 2024Indiva Limited Provided Earnings Guidance for the First Quarter and fiscal year 2024. For the quarter, the company expects net revenue will be lower on a sequential basis, primarily due to seasonality, and flat year-over-year, due to the continued growth in Pearls by Grön, and the contribution to revenue from No Future gummies and Indiva Blips offset by Wana converting to contract manufacturing and the loss of lozenge revenue.For the year, the company expects to generate record net revenue, driven by continued strength in its core brands, bolstered by new product introductions and continued efficiency gains at the production facility from automation and process improvements.Reported Earnings • Apr 26Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.081 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.081 loss in FY 2022). Revenue: CA$37.6m (up 9.2% from FY 2022). Net loss: CA$4.92m (loss narrowed 55% from FY 2022). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.お知らせ • Apr 17Indiva Limited to Report Q4, 2023 Results on Apr 25, 2024Indiva Limited announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024New Risk • Apr 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.30m (US$7.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 3.6% per year over the past 5 years. Market cap is less than US$10m (€7.30m market cap, or US$7.91m). Minor Risk Shareholders have been diluted in the past year (33% increase in shares outstanding).Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Rachel Goldman was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 28Indiva Limited announced that it expects to receive CAD 4.312 million in fundingIndiva Limited announce a non-brokered private placement of up to 30,800,000 units at a price of CAD 0.14 per unit for aggregate gross proceeds of up to CAD 4,312,000 on February 28, 2024. Each unit will consist of one common share and one-half common share purchase warrant. Each warrant will be exercisable into one common share at a price of CAD 0.15 per common share for a period of 36 months from the date of issuance. The closing of the offerings may take place in one or more tranches. The offerings are subject to certain conditions including, but not limited to, the approval of the TSXV. The company may pay certain eligible finders a finder's fee of up to CAD 400,000.お知らせ • Jan 22Indiva Limited announced that it expects to receive CAD 4 million in fundingIndiva Limited announces private placement of minimum of 20,000,000 units and maximum of 40,000,000 Units at an issue price of CAD 0.10 per unit for gross proceeds of CAD 2,000,000 incase of minimum offering and CAD 4,000,000 incase of maximum offering on January 22, 2024. Each Unit consists of one common share and one-half Common Share purchase warrant. Each Warrant is exercisable into one Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the date of issuance. The Warrants will be governed by the terms and conditions set forth in the certificates representing the Warrants. The transaction is expected to close the final tranche closing will occur no later than March 7, 2024. The company will pay finder's cash fee 8% of the gross proceeds raised in respect of the Offering from subscribers and also issue to eligible finders such number of finder warrants equal to 8.0% of the number of Units sold under the Offering to subscribers introduced by such finders to the Company. The Finder Warrants, to the extent they are issued, shall entitle the holder thereof to acquire one Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the date of issuance.Reported Earnings • Nov 24Third quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.018 loss in 3Q 2022)Third quarter 2023 results: CA$0.005 loss per share (improved from CA$0.018 loss in 3Q 2022). Revenue: CA$9.79m (up 21% from 3Q 2022). Net loss: CA$902.2k (loss narrowed 65% from 3Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.お知らせ • Nov 22Indiva Limited Provides Revenue Guidance for Fourth Quarter of 2023Indiva Limited provided revenue guidance for fourth quarter of 2023. The company expects fourth quarter of 2023 net revenue, excluding contract manufacturing, to improve sequentially driven by new product introduction, including first full quarter of No Future sales across Canada. New SKUs coming to market include additional No Future gummies and vapes, Blips, as well as new 5-count and 25-count Pearls gummies. Gross margins are expected to continue to trend higher over time as the Company benefits from a mix shift to higher margin products and continues to achieve further production efficiencies driven by greater utilization of automation in production and packaging activities.お知らせ • Nov 04Indiva Limited to Report Q3, 2023 Results on Nov 21, 2023Indiva Limited announced that they will report Q3, 2023 results Pre-Market on Nov 21, 2023Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.017 loss in 2Q 2022)Second quarter 2023 results: CA$0.006 loss per share (improved from CA$0.017 loss in 2Q 2022). Revenue: CA$7.51m (down 7.6% from 2Q 2022). Net loss: CA$994.8k (loss narrowed 60% from 2Q 2022). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.お知らせ • Aug 18Indiva Limited to Report Q2, 2023 Results on Aug 29, 2023Indiva Limited announced that they will report Q2, 2023 results Pre-Market on Aug 29, 2023お知らせ • Aug 11Indiva Limited Launches No Future Gummies and VapesIndiva Limited introduced a new value-focused cannabis brand called No Future, which the Company has already begun shipping to B.C. and Alberta and is expected to ship to Ontario in September 2023. No Future is intended to fill a large and critical gap in the cannabis marketplace that opened once the ingestible extracts market was eliminated earlier this year. Indiva expects No Future to accelerate the migration of consumers from the illicit market to the legal market by drastically reducing the price per milligram of THC in cannabis edibles and other extract products such as vapes. No Future will initially launch with four flavours of THC gummies and three varieties of 1.2g 510 vapes. No Future THC Gummies will be 10mg THC per pack and retail prices are expected to reset the floor price of legal market gummies across Canada, with some stores selling at similar prices per mg of THC as ingestible extracts were sold. No Future Vapes will be sold in 1.2g 510 thread cartridges and introduced in three great-tasting strains: Sour Tangie (Sativa), Cherry Zlushie (Hybrid), and Hot CKS (Indica). Similar to No Future gummies, Indiva expects this set of products to reset the floor price of legal 1.2g vapes across Canada. B.C. and Alberta have already begun to receive their first shipments of No Future gummies and Ontario is expected to receive its first shipments in September 2023 and be in stock at retailers by October 2023. No Future Vapes have been delivered in Alberta and are expected to land in Ontario on the same timeline as the gummies. Indiva plans for more regions and product launches to come online in the fall and winter of 2023.New Risk • Jun 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-CA$36k). Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (€3.22m market cap, or US$3.52m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).お知らせ • May 31Indiva Limited announced that it expects to receive CAD 2.155617 million in funding from Canopy Growth CorporationIndiva Limited announced that it has entered a non-brokered private placement of 37,230,000 common shares at a price of CAD 0.0579 per share for gross proceeds of CAD 2,155,617 on May 30, 2023. The transaction will include participation from new investor, Canopy Growth Corporation. The balance of the consideration will be paid by Canopy Growth Corporation to the company as additional consideration representing a value of CAD 844,383 and cash payment of CAD 1,250,000 on May 30, 2024. The private placement is expected to close on or before June 6, 2023. The transaction is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The common shares to be issued under the private placement will have a hold period of four months and one day from the closing date.お知らせ • May 17Indiva Limited Provides Revenue Guidance for the Second Quarter of 2023Indiva Limited provided revenue guidance for the second quarter of 2023. The company expects second quarter of 2023 net revenue to improve compared to the same period last year; however, there is risk that net revenue may decline sequentially, if sales of new products fail to offset lower sales of ingestible extracts as a result of Health Canada's recent order to stop production and sale of these products. Sequential growth in net revenue is expected to resume in the second half of 2023 driven by the introduction of new products in the third and fourth quarters, resulting primarily from in-house innovation. Gross margins are expected to continue to trend higher and benefit from the implementation of automation in the production and packaging of edible products.お知らせ • May 12Indiva Limited, Annual General Meeting, Jul 18, 2023Indiva Limited, Annual General Meeting, Jul 18, 2023.お知らせ • May 04Indiva Limited to Report Q1, 2023 Results on May 16, 2023Indiva Limited announced that they will report Q1, 2023 results Pre-Market on May 16, 2023Reported Earnings • Apr 19Full year 2022 earnings released: CA$0.081 loss per share (vs CA$0.11 loss in FY 2021)Full year 2022 results: CA$0.081 loss per share (improved from CA$0.11 loss in FY 2021). Revenue: CA$34.4m (up 6.0% from FY 2021). Net loss: CA$10.9m (loss narrowed 27% from FY 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 22Third quarter 2022 earnings released: CA$0.018 loss per share (vs CA$0.047 loss in 3Q 2021)Third quarter 2022 results: CA$0.018 loss per share (improved from CA$0.047 loss in 3Q 2021). Revenue: CA$8.09m (up 4.8% from 3Q 2021). Net loss: CA$2.57m (loss narrowed 60% from 3Q 2021). Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 18Second quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.011 loss in 2Q 2021)Second quarter 2022 results: CA$0.017 loss per share (down from CA$0.011 loss in 2Q 2021). Revenue: CA$8.13m (down 9.7% from 2Q 2021). Net loss: CA$2.50m (loss widened 69% from 2Q 2021). Over the next year, revenue is forecast to grow 51%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 27Full year 2021 earnings released: CA$0.11 loss per share (vs CA$0.16 loss in FY 2020)Full year 2021 results: CA$0.11 loss per share (up from CA$0.16 loss in FY 2020). Revenue: CA$32.5m (up 122% from FY 2020). Net loss: CA$15.0m (loss narrowed 2.7% from FY 2020). Over the next year, revenue is forecast to grow 29%, compared to a 7.9% growth forecast for the pharmaceuticals industry in Germany.Reported Earnings • Nov 17Third quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.035 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: CA$7.72m (up 155% from 3Q 2020). Net loss: CA$6.43m (loss widened 80% from 3Q 2020).Reported Earnings • Aug 25Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.029 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$9.08m (up 255% from 2Q 2020). Net loss: CA$1.42m (loss narrowed 44% from 2Q 2020).Reported Earnings • Jun 02First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.029 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: CA$6.22m (up 209% from 1Q 2020). Net loss: CA$3.03m (loss widened 24% from 1Q 2020).Reported Earnings • May 16Full year 2020 earnings released: CA$0.16 loss per share (vs CA$0.14 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: CA$14.7m (up CA$13.7m from FY 2019). Net loss: CA$15.4m (loss widened 35% from FY 2019).Is New 90 Day High Low • Feb 04New 90-day high: €0.28The company is up 91% from its price of €0.15 on 05 November 2020. The German market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Jan 12New 90-day high: €0.20The company is up 32% from its price of €0.15 on 14 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period.Recent Insider Transactions • Dec 26Independent Director recently bought €42k worth of stockOn the 18th of December, Andre Lafleche bought around 290k shares on-market at roughly €0.14 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €77k more in shares than they have sold in the last 12 months.Reported Earnings • Nov 27Third quarter 2020 earnings released: CA$0.035 loss per shareThe company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: CA$3.03m (up CA$2.84m from 3Q 2019). Net loss: CA$3.57m (loss widened 36% from 3Q 2019).株主還元T8RPDE PharmaceuticalsDE 市場7D0%-4.2%-0.8%1Y-47.4%39.5%-0.9%株主還元を見る業界別リターン: T8RP過去 1 年間で39.5 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: T8RPは、過去 1 年間で-0.9 % のリターンを上げたGerman市場を下回りました。価格変動Is T8RP's price volatile compared to industry and market?T8RP volatilityT8RP Average Weekly Movementn/aPharmaceuticals Industry Average Movement6.0%Market Average Movement5.4%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: T8RPの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のT8RPのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aNiel Marottawww.indiva.comインディバ・リミテッドはカナダで大麻と大麻関連製品の製造、加工、販売を行っている。No Future、Pearls by gron、Bhang Chocolate、Indiva Doppio、Indiva Blips、Indiva 1432のブランドでエディブル、カプセル、タブレット、VAPE製品を提供している。インディバ・リミテッドはカナダのオタワに本社を置いている。もっと見るIndiva Limited 基礎のまとめIndiva の収益と売上を時価総額と比較するとどうか。T8RP 基礎統計学時価総額€3.92m収益（TTM）-€2.96m売上高(TTM)€25.03m0.2xP/Sレシオ-1.3xPER（株価収益率T8RP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計T8RP 損益計算書（TTM）収益CA$37.49m売上原価CA$26.54m売上総利益CA$10.95mその他の費用CA$15.39m収益-CA$4.44m直近の収益報告Mar 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.023グロス・マージン29.21%純利益率-11.83%有利子負債／自己資本比率-1,692.6%T8RP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/09/10 05:21終値2024/06/13 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Indiva Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Siddharth RajeevFundamental Research Corp.Rahul SarugaserRaymond James Ltd.Greg McLeishResearch Capital Corporation
お知らせ • Nov 06SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H).SNDL Inc. (NasdaqCM:SNDL) enters into a stalking horse purchase agreement to acquire a remaining majority stake in Indiva Limited (TSXV:NDVA.H) for CAD 22.7 million on July 5, 2024. PricewaterhouseCoopers Inc. (The Monitor) currently estimates the value of the credit bid and cash consideration payable by SNDL under the Bid Agreement to be in the range of approximately CAD 25 million to CAD 28 million. As of July 8, 2024, the Court has approved the sale process. The Transaction is anticipated to close during SNDL's fourth quarter following the receipt of all such approvals. Indiva will seek approval for the Transaction from the Court on or about September 19, 2024. As per filing on August 29, 2024, stalking horse bid of SNDL has been chosen as the successful bid in the acquisition of Indiva. McCarthy Tétrault LLP is acting as legal counsel for SNDL, Bennett Jones LLP is acting as legal counsel for the Indiva Group, and Osler Hoskin & Harcourt LLP is acting as legal counsel for PricewaterhouseCoopers Inc. (the monitor). SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H) on November 4, 2024.
お知らせ • Jun 15Indiva Limited Announces Resignation of Rachel Goldman from the BoardIndiva announced that Rachel Goldman resigned from the board of Indiva on June 12, 2024, prior to the board resolving to commence proceedings under the CCAA.
New Risk • Jun 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.6m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-CA$1.3m). Market cap is less than US$10m (€4.59m market cap, or US$5.00m). Minor Risk Shareholders have been diluted in the past year (31% increase in shares outstanding).
お知らせ • May 24Indiva Limited Provides Earnings Guidance for the Second Quarter of 2024Indiva Limited Provided Earnings Guidance for the second Quarter of 2024. For the quarter, the company expects net revenue will be higher on a sequential basis and year-over-year, expected to exceed $10 million, based on the strength of purchase orders from provincial wholesalers and deliveries to date in the quarter.
お知らせ • May 16Indiva Limited to Report Q1, 2024 Results on May 23, 2024Indiva Limited announced that they will report Q1, 2024 results Pre-Market on May 23, 2024
お知らせ • Apr 27Indiva Limited Provides Earnings Guidance for the First Quarter and Fiscal Year 2024Indiva Limited Provided Earnings Guidance for the First Quarter and fiscal year 2024. For the quarter, the company expects net revenue will be lower on a sequential basis, primarily due to seasonality, and flat year-over-year, due to the continued growth in Pearls by Grön, and the contribution to revenue from No Future gummies and Indiva Blips offset by Wana converting to contract manufacturing and the loss of lozenge revenue.For the year, the company expects to generate record net revenue, driven by continued strength in its core brands, bolstered by new product introductions and continued efficiency gains at the production facility from automation and process improvements.
お知らせ • Nov 06SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H).SNDL Inc. (NasdaqCM:SNDL) enters into a stalking horse purchase agreement to acquire a remaining majority stake in Indiva Limited (TSXV:NDVA.H) for CAD 22.7 million on July 5, 2024. PricewaterhouseCoopers Inc. (The Monitor) currently estimates the value of the credit bid and cash consideration payable by SNDL under the Bid Agreement to be in the range of approximately CAD 25 million to CAD 28 million. As of July 8, 2024, the Court has approved the sale process. The Transaction is anticipated to close during SNDL's fourth quarter following the receipt of all such approvals. Indiva will seek approval for the Transaction from the Court on or about September 19, 2024. As per filing on August 29, 2024, stalking horse bid of SNDL has been chosen as the successful bid in the acquisition of Indiva. McCarthy Tétrault LLP is acting as legal counsel for SNDL, Bennett Jones LLP is acting as legal counsel for the Indiva Group, and Osler Hoskin & Harcourt LLP is acting as legal counsel for PricewaterhouseCoopers Inc. (the monitor). SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H) on November 4, 2024.
お知らせ • Jun 15Indiva Limited Announces Resignation of Rachel Goldman from the BoardIndiva announced that Rachel Goldman resigned from the board of Indiva on June 12, 2024, prior to the board resolving to commence proceedings under the CCAA.
New Risk • Jun 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.6m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-CA$1.3m). Market cap is less than US$10m (€4.59m market cap, or US$5.00m). Minor Risk Shareholders have been diluted in the past year (31% increase in shares outstanding).
お知らせ • May 24Indiva Limited Provides Earnings Guidance for the Second Quarter of 2024Indiva Limited Provided Earnings Guidance for the second Quarter of 2024. For the quarter, the company expects net revenue will be higher on a sequential basis and year-over-year, expected to exceed $10 million, based on the strength of purchase orders from provincial wholesalers and deliveries to date in the quarter.
お知らせ • May 16Indiva Limited to Report Q1, 2024 Results on May 23, 2024Indiva Limited announced that they will report Q1, 2024 results Pre-Market on May 23, 2024
お知らせ • Apr 27Indiva Limited Provides Earnings Guidance for the First Quarter and Fiscal Year 2024Indiva Limited Provided Earnings Guidance for the First Quarter and fiscal year 2024. For the quarter, the company expects net revenue will be lower on a sequential basis, primarily due to seasonality, and flat year-over-year, due to the continued growth in Pearls by Grön, and the contribution to revenue from No Future gummies and Indiva Blips offset by Wana converting to contract manufacturing and the loss of lozenge revenue.For the year, the company expects to generate record net revenue, driven by continued strength in its core brands, bolstered by new product introductions and continued efficiency gains at the production facility from automation and process improvements.
Reported Earnings • Apr 26Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.081 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.081 loss in FY 2022). Revenue: CA$37.6m (up 9.2% from FY 2022). Net loss: CA$4.92m (loss narrowed 55% from FY 2022). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
お知らせ • Apr 17Indiva Limited to Report Q4, 2023 Results on Apr 25, 2024Indiva Limited announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024
New Risk • Apr 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.30m (US$7.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 3.6% per year over the past 5 years. Market cap is less than US$10m (€7.30m market cap, or US$7.91m). Minor Risk Shareholders have been diluted in the past year (33% increase in shares outstanding).
Board Change • Apr 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Rachel Goldman was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 28Indiva Limited announced that it expects to receive CAD 4.312 million in fundingIndiva Limited announce a non-brokered private placement of up to 30,800,000 units at a price of CAD 0.14 per unit for aggregate gross proceeds of up to CAD 4,312,000 on February 28, 2024. Each unit will consist of one common share and one-half common share purchase warrant. Each warrant will be exercisable into one common share at a price of CAD 0.15 per common share for a period of 36 months from the date of issuance. The closing of the offerings may take place in one or more tranches. The offerings are subject to certain conditions including, but not limited to, the approval of the TSXV. The company may pay certain eligible finders a finder's fee of up to CAD 400,000.
お知らせ • Jan 22Indiva Limited announced that it expects to receive CAD 4 million in fundingIndiva Limited announces private placement of minimum of 20,000,000 units and maximum of 40,000,000 Units at an issue price of CAD 0.10 per unit for gross proceeds of CAD 2,000,000 incase of minimum offering and CAD 4,000,000 incase of maximum offering on January 22, 2024. Each Unit consists of one common share and one-half Common Share purchase warrant. Each Warrant is exercisable into one Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the date of issuance. The Warrants will be governed by the terms and conditions set forth in the certificates representing the Warrants. The transaction is expected to close the final tranche closing will occur no later than March 7, 2024. The company will pay finder's cash fee 8% of the gross proceeds raised in respect of the Offering from subscribers and also issue to eligible finders such number of finder warrants equal to 8.0% of the number of Units sold under the Offering to subscribers introduced by such finders to the Company. The Finder Warrants, to the extent they are issued, shall entitle the holder thereof to acquire one Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the date of issuance.
Reported Earnings • Nov 24Third quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.018 loss in 3Q 2022)Third quarter 2023 results: CA$0.005 loss per share (improved from CA$0.018 loss in 3Q 2022). Revenue: CA$9.79m (up 21% from 3Q 2022). Net loss: CA$902.2k (loss narrowed 65% from 3Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
お知らせ • Nov 22Indiva Limited Provides Revenue Guidance for Fourth Quarter of 2023Indiva Limited provided revenue guidance for fourth quarter of 2023. The company expects fourth quarter of 2023 net revenue, excluding contract manufacturing, to improve sequentially driven by new product introduction, including first full quarter of No Future sales across Canada. New SKUs coming to market include additional No Future gummies and vapes, Blips, as well as new 5-count and 25-count Pearls gummies. Gross margins are expected to continue to trend higher over time as the Company benefits from a mix shift to higher margin products and continues to achieve further production efficiencies driven by greater utilization of automation in production and packaging activities.
お知らせ • Nov 04Indiva Limited to Report Q3, 2023 Results on Nov 21, 2023Indiva Limited announced that they will report Q3, 2023 results Pre-Market on Nov 21, 2023
Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.017 loss in 2Q 2022)Second quarter 2023 results: CA$0.006 loss per share (improved from CA$0.017 loss in 2Q 2022). Revenue: CA$7.51m (down 7.6% from 2Q 2022). Net loss: CA$994.8k (loss narrowed 60% from 2Q 2022). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
お知らせ • Aug 18Indiva Limited to Report Q2, 2023 Results on Aug 29, 2023Indiva Limited announced that they will report Q2, 2023 results Pre-Market on Aug 29, 2023
お知らせ • Aug 11Indiva Limited Launches No Future Gummies and VapesIndiva Limited introduced a new value-focused cannabis brand called No Future, which the Company has already begun shipping to B.C. and Alberta and is expected to ship to Ontario in September 2023. No Future is intended to fill a large and critical gap in the cannabis marketplace that opened once the ingestible extracts market was eliminated earlier this year. Indiva expects No Future to accelerate the migration of consumers from the illicit market to the legal market by drastically reducing the price per milligram of THC in cannabis edibles and other extract products such as vapes. No Future will initially launch with four flavours of THC gummies and three varieties of 1.2g 510 vapes. No Future THC Gummies will be 10mg THC per pack and retail prices are expected to reset the floor price of legal market gummies across Canada, with some stores selling at similar prices per mg of THC as ingestible extracts were sold. No Future Vapes will be sold in 1.2g 510 thread cartridges and introduced in three great-tasting strains: Sour Tangie (Sativa), Cherry Zlushie (Hybrid), and Hot CKS (Indica). Similar to No Future gummies, Indiva expects this set of products to reset the floor price of legal 1.2g vapes across Canada. B.C. and Alberta have already begun to receive their first shipments of No Future gummies and Ontario is expected to receive its first shipments in September 2023 and be in stock at retailers by October 2023. No Future Vapes have been delivered in Alberta and are expected to land in Ontario on the same timeline as the gummies. Indiva plans for more regions and product launches to come online in the fall and winter of 2023.
New Risk • Jun 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-CA$36k). Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (€3.22m market cap, or US$3.52m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
お知らせ • May 31Indiva Limited announced that it expects to receive CAD 2.155617 million in funding from Canopy Growth CorporationIndiva Limited announced that it has entered a non-brokered private placement of 37,230,000 common shares at a price of CAD 0.0579 per share for gross proceeds of CAD 2,155,617 on May 30, 2023. The transaction will include participation from new investor, Canopy Growth Corporation. The balance of the consideration will be paid by Canopy Growth Corporation to the company as additional consideration representing a value of CAD 844,383 and cash payment of CAD 1,250,000 on May 30, 2024. The private placement is expected to close on or before June 6, 2023. The transaction is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The common shares to be issued under the private placement will have a hold period of four months and one day from the closing date.
お知らせ • May 17Indiva Limited Provides Revenue Guidance for the Second Quarter of 2023Indiva Limited provided revenue guidance for the second quarter of 2023. The company expects second quarter of 2023 net revenue to improve compared to the same period last year; however, there is risk that net revenue may decline sequentially, if sales of new products fail to offset lower sales of ingestible extracts as a result of Health Canada's recent order to stop production and sale of these products. Sequential growth in net revenue is expected to resume in the second half of 2023 driven by the introduction of new products in the third and fourth quarters, resulting primarily from in-house innovation. Gross margins are expected to continue to trend higher and benefit from the implementation of automation in the production and packaging of edible products.
お知らせ • May 12Indiva Limited, Annual General Meeting, Jul 18, 2023Indiva Limited, Annual General Meeting, Jul 18, 2023.
お知らせ • May 04Indiva Limited to Report Q1, 2023 Results on May 16, 2023Indiva Limited announced that they will report Q1, 2023 results Pre-Market on May 16, 2023
Reported Earnings • Apr 19Full year 2022 earnings released: CA$0.081 loss per share (vs CA$0.11 loss in FY 2021)Full year 2022 results: CA$0.081 loss per share (improved from CA$0.11 loss in FY 2021). Revenue: CA$34.4m (up 6.0% from FY 2021). Net loss: CA$10.9m (loss narrowed 27% from FY 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 22Third quarter 2022 earnings released: CA$0.018 loss per share (vs CA$0.047 loss in 3Q 2021)Third quarter 2022 results: CA$0.018 loss per share (improved from CA$0.047 loss in 3Q 2021). Revenue: CA$8.09m (up 4.8% from 3Q 2021). Net loss: CA$2.57m (loss narrowed 60% from 3Q 2021). Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 18Second quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.011 loss in 2Q 2021)Second quarter 2022 results: CA$0.017 loss per share (down from CA$0.011 loss in 2Q 2021). Revenue: CA$8.13m (down 9.7% from 2Q 2021). Net loss: CA$2.50m (loss widened 69% from 2Q 2021). Over the next year, revenue is forecast to grow 51%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 27Full year 2021 earnings released: CA$0.11 loss per share (vs CA$0.16 loss in FY 2020)Full year 2021 results: CA$0.11 loss per share (up from CA$0.16 loss in FY 2020). Revenue: CA$32.5m (up 122% from FY 2020). Net loss: CA$15.0m (loss narrowed 2.7% from FY 2020). Over the next year, revenue is forecast to grow 29%, compared to a 7.9% growth forecast for the pharmaceuticals industry in Germany.
Reported Earnings • Nov 17Third quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.035 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: CA$7.72m (up 155% from 3Q 2020). Net loss: CA$6.43m (loss widened 80% from 3Q 2020).
Reported Earnings • Aug 25Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.029 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$9.08m (up 255% from 2Q 2020). Net loss: CA$1.42m (loss narrowed 44% from 2Q 2020).
Reported Earnings • Jun 02First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.029 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: CA$6.22m (up 209% from 1Q 2020). Net loss: CA$3.03m (loss widened 24% from 1Q 2020).
Reported Earnings • May 16Full year 2020 earnings released: CA$0.16 loss per share (vs CA$0.14 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: CA$14.7m (up CA$13.7m from FY 2019). Net loss: CA$15.4m (loss widened 35% from FY 2019).
Is New 90 Day High Low • Feb 04New 90-day high: €0.28The company is up 91% from its price of €0.15 on 05 November 2020. The German market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Jan 12New 90-day high: €0.20The company is up 32% from its price of €0.15 on 14 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period.
Recent Insider Transactions • Dec 26Independent Director recently bought €42k worth of stockOn the 18th of December, Andre Lafleche bought around 290k shares on-market at roughly €0.14 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €77k more in shares than they have sold in the last 12 months.
Reported Earnings • Nov 27Third quarter 2020 earnings released: CA$0.035 loss per shareThe company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: CA$3.03m (up CA$2.84m from 3Q 2019). Net loss: CA$3.57m (loss widened 36% from 3Q 2019).
